ALFA Finder| Management target | Revenue FY27 |
|---|
| Revenue growth | 23.1% YoY decline in Q1 FY27 |
|---|---|
| Margins | Gross margin at 71.5%; EBITDA margin at 2.2% |
| Order book | Sapala has meaningful order visibility for FY27 |
| Demand visibility | Healthy API order book; 140+ active CDMO projects |
| Management confidence | High for H2 recovery and long-term pipeline |
Growth
Revenue down 23.1% YoY. Pharma CDMO fell 38.7%; API+ fell 10.4%; Specialty Chemicals fell 34.7%.
Outlook
FY27 growth weighted towards H2. Investing INR 598 Mn capex; expanding Sapala stake for nucleic-acid business leadership.
Risks
Unfavorable product mix, negative operating leverage, and subsidiary consolidation (NJ Bio losses) pressured margins.
Last quarter's promises, checked
Delivered
- Guided Q1 FY27 to be low point → delivered INR 92 Mn EBITDA (= BEAT)
- Guided FY26 Gross Margin ~70.8% → delivered 71.5% in Q1 (= BEAT)
- Guided H1 FY27 to be weak → delivered 23.1% revenue decline (= BEAT)
Partly delivered
- Guided recovery from H2 FY27 → current results show 38.7% CDMO fall (= PARTIAL)
Missed
- Guided FY27 Capex INR 3,000 Mn → delivered INR 598 Mn in Q1 (= MISS)
Investor Presentation filed with NSE, NSE: COHANCE. Summary written with AI assistance from the document.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹460.10
- Market cap
- ₹17,604 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 371.6×Sector 43.8×
- Promoter holding
- 57.48%-0.01% QoQ
- FII holding
- 7.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Capital Structure Change
Jasti group entities transferred 51,00,000 Cohance shares to Jasub Property Holdings LLP via inter-se block deals. Combined group holding remains 6.36%.
Cohance Lifesciences Business Update
Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.
Cohance Lifesciences Management Change
Cohance Lifesciences appointed Kuber Jagdale as Executive Director for 60 months, effective 7 November 2026. He brings over three decades of pharmaceutical manufacturing and operations experience.
Cohance Lifesciences Earnings Call Transcript: Key Takeaways
Q2 revenue rose about 13% QoQ to ₹477 Cr and adjusted EBITDA reached about ₹46 Cr (~10% margin), but both remain below last year. H2 YoY growth is promised without figures, and FY27 specialty chemicals guidance was cut to decline.
Cohance Lifesciences Results Update
Cohance Lifesciences issued a press release on its unaudited Q2 and H1 FY27 results. It reported lower year-on-year revenue and an expected stronger second half.
Cohance Lifesciences Investor Presentation: Key Takeaways
Q2FY27 revenue INR 4,766 Mn, down 14.2% YoY but up 12.9% QoQ. Adjusted EBITDA margin 9.6%, adjusted PAT INR 74 Mn back positive. Strategy centres on One Cohance integration and H2 recovery.